��ժҪ��Ϣ

[an error occurred while processing this directive]

��Ƥ��Բ�ѧ��־ 2001, 27(2) 67-70 DOI: ISSN: 2096-5540 CN: 32-1880/R

��Ŀ¼ | ��Ŀ¼ | �� | �߼�� [��ӡ��ҳ] [�ر�]

��

	��չ��

	��Ϣ
	Supporting info
	PDFȫ��
	[HTMLȫ��]
	�ο��
	��뷴��
	�ѱ��Ƽ��
	��ҵ��
	��ù��
	��ñ��
	Email Alert
	��·��
	��Ϣ
	��Ĺؼ��
	��м��
	ҩ��
	ҩ��ѧ
	��
	��
	�ܺ��
	֣��У
	PubMed
	Article by
	Article by

һЩ��м��ҩ��ҩ��ٴ��о�

�ܺ��, ֣��У

�й�ҽѧ��ѧԺ��й�Э��ҽ�ƴ�ѧƤ��о��

ժҪ��

��˽��ױ��м��Ƶ��¡��ҩ��ҩЧ��ܵ��û��Ƶ��о��չ,��άA�ᡢά��D����ء��ࡢ��ӡ��Ӻ��ᡢù��,��,��һЩĿǰ��ٴ��׶��δ��г��ҩ��Ʒ,��Ѫ��Ƽ��Tϸ���ź��ϼ��.

�ؼ���� м�� ҩ�� ҩ��ѧ ��

Abstract:

Keywords:

�ո�� �޻�� ��淢��

DOI:

��Ŀ:

ͨѶ��:

��߼��:

�ο��ף�

[1] Sanrat JH.Retinoids and psoriasis:novel issues in retinoid pharmacology and implic ations for psoriasis treatment.J Am Acad Dermatol,1999,41(3 pt 2):S2-S6.
[2] Larscn FG,Jakobscn P,Knudscn J,et al.Conversion of acitretin to etretinate in psoriatic patients is influenced by ethanol.J Invest Dermatol,1993,100(5):623-627.
[3] van de Kerkhof PCM.An update on Vitamin D3 anologues in the treatment of psoriasis.Skin Pharmacol,1998,11:2-10.
[4] Bektas M,Orfanos CE,Geilen CC.Different vitamin D analogues induce sphingomyelin hydrolysis and apoptosis in the human keratinocyte cell line HaCaT.Cell Mol Biol,2000,46(1):111-119.
[5] Guzzo C.Recent advances in the treatment of psoriasis.Dermatol Clin,1997.15(1):59-68.
[6] Fisher GJ,Duell EA,Nickoloff BJ,et al.Levels of cyclosporin in epidermis of treated psoriasis patients differentially inhibit growth of keratinocytes cultured in scrum free versus serum containing media.J Invest Dermatol,1988,91(2):142-146.
[7] Kaplan A,Matsue H,Shibaki A,et al.The effects of cyclosporin A and FK506 on proliferation and IL-8 production of cultured human ker-atinocytes.J Dermatol Sci,1995,10(2):130-138.
[8] Xemitz A,Reitamo S,Erkko P,et al.Tgcrolimus ointment improves psoriasis in a microplaque assay.Br J Dermatol,1999,141(1):103-107.
[9] Mrowietz U,Graeber M,Brantigam M,et al.The novel ascomycin deri.ative SDZ ASM 981 is effective for psoriasis when used topically under occlnsion.Br J Dermatol,1998,139(6):992-996.
[10] Hegemann L,Fruchtmann R,van Rooijen LA,et al.The antipsoriatic drug,anthralin,inhibits protein kinase C-implications for its mechanisn of action.Arch Dermatol Res,1992,284(3):179-183.
[11] Lange RW,Hayden PJ,Chignell CF,et al.Anthralin stimulates ker atinocyte-derived proinflammatory cytokines via generation of reactive oxygen species.Inflamm Res,1998,47(4):174-181.
[12] Gottlieb AB,Khandke L,Krane JF,et al.Anthralin decreases keratinocvte TGF-alpha expression and EGF-receptor binding in vitro.J Invest Dermatol,1992,98(5):680-685.
[13] Mrowietz U,Jessat H,Schwarz A,et al.Anthralin(di thranol) in vitro inhibits human monocytes to secrete IL-6IL-8 and TNF-��,but not IL-1.Br J Dermatol,1997,136(4):542-547.
[14] Chodorowska G.Plasma concentrations of IFN-gamma and TNF-alpha in psoriatic patients before and after local treatment with dithranol ointment.J Eur Acad Dermatol Venereol,1998,10(2):147-151.
[15] Peus D,Beyerle A,Rittner HL,et al.Anti-psoriatic drug anthralin activates JNK via lipid peroxidation:mononuclear cells are more sensitive than keratinocytes.J Invest Deratol,2000,114(4):688-692.
[16] Parslew R,Friedmann PS.The irritancy of anthralin is inbited by repeat application of a subirritant concentration.Br J Dermatol,1999,141(3):469-474.
[17] Ockenfels HM,Schultewolter T,Ockenfels G,et al.The antipsoriatic agent dimethylfumarate immunomodulates T-cell cytokine seretion and inhibits cytokines of the psoriatic cytokine network.Br J Dermatol,1998,139(3):390-395.
[18] Asadullah K,Schmid H,Friedrich M,et al.Inffluence of monomethylfumarate on monocytic cytokine formation-explanation for adversc and therapeutic effects in psoriasis.Arch Dermatol Res,1997,289(11):623-630.
[19] Vanderrmeeren M,Janssens S,Borgers M,et al.Dimethylfumarate is an inhibitor of cytokine-induced E-sclectin,VCAM-1,and ICAM-1 expression in human endothelial cells.Biochem Biophys Res Commun,1997,234(1):19-23.
[20] Kirby B,Yates VM.Mycophenolate mofetil for psoriasis.Br J Dermatol,1998,139(2):357.
[21] Geilen CC,Mrowietz U.Lack of efficacy of topical mycophenolic acid in psoriasis vulgaris.J Mm Acad Dermatol,2000,42(5 Ptl):837-840.
[22] Gottlieb A,Krueger JG,Bright R,et al.Effects of administration of a single dose of a humanized monoclonal antibody to CD1 la on the immunobiology and clinical activity of p,oriasis.J Am Acad Dermatol,2000,42(3):428-435.
[23] Abrarms JR,Lebwohl MG,Guzzo CA,et al.CTLA4Ig-mediated blockade of T cell costimulation in patients with psoriasis vulgaris.J Clin Invest,1999,103(9):1243-1252.
[24] Magilavy D,Mant T,Norman P,et al.Pharmacodynamic effects of LFA3T1P(Amevive) in patients with chronic plaque psoriasis(CPP):sclective modulation of CD45RO + lymphocytes.J Invest Dermatol,1999,112:609(abstr).
[25] Bagel J,Garland WT,Breneman D,et al.Administration of DAB389IL2 to patients with recalcitrant psoriasis:a double-blind,phase �� muhicenter trial.J Am Acad Dermatol,1998,38:938-944.
[26] Balagon MV,Walsh DS,Tan PL,et al.Improvement in psoriasis after intradermal administration of heat-killed Mycobacterium vaccae.Int J Dermatol,2000,39(1):51-58.
[27] Dupont E,Savard PE,Jourdain C,et al.Antiangiogenic properties of a novel shark cartilage extract:potential role in the treatment of psoriasis.J Cutan Med Surg,1998,2(3):146-152.